CINCinactive
CinCor Pharma, Inc.
Biopharma developer (SEC filing verified)·Phase 2
CardiovascularNephrology
CINC evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Lead Asset:
- baxdrostat
What it means
The company data is ready for cross-source review; unsupported conclusions remain unknown.
What to watch
BioSniper Score: 5.3 / 10 · Lead Asset: baxdrostat
BioSniper AIPage evidence connected
Prepared research question
What matters most for CINC—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
5.3/10
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates for CinCor Pharma, Inc..
Run CinCor Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CinCor Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash RunwayN/A
Cash runway data unavailable
Financial HealthN/A
Financial health data unavailable
Pipeline Maturity6.0
Lead: Phase 2
Pipeline Breadth4.6
2 candidates
Catalyst MomentumN/A
No upcoming catalysts tracked
Insider SignalN/A
No insider transactions in the last 180 days
Pipeline
923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.